Recent promising results of clinical trials with an ALK inhibitor, crizotinib, have changed the significance of ALK fusions in lung cancer [3], [4], [5], [6], inflammatory myofibroblastic tumors (IMTs) [7], and ALCL [8]. This evidence concerns the gene ALK and lung cancer.